--- title: "Retatrutide vs Tirzepatide: Side-by-Side Comparison (2026)" description: "Compare Retatrutide vs Tirzepatide — mechanism, half-life, dose range, side effects, and live vendor pricing. Retatrutide from $79.99. Tirzepatide from $49.00." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compare", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Retatrutide vs Tirzepatide" } ] }, { "@context": "https://schema.org", "@type": "WebPage", "name": "Retatrutide vs Tirzepatide: Side-by-Side Comparison (2026)", "description": "Compare Retatrutide vs Tirzepatide — mechanism, half-life, dose range, side effects, and live vendor pricing. Retatrutide from $79.99. Tirzepatide from $49.00. Side-by-side data from BodyHackGuide — we earn a commission on some vendor links.", "url": "https://www.bodyhackguide.co/compare/retatrutide-vs-tirzepatide", "dateModified": "2026-09-07", "isPartOf": { "@type": "WebSite", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainEntity": { "@type": "ItemList", "itemListElement": [ { "@type": "ListItem", "position": 1, "item": { "@type": "Product", "name": "Retatrutide", "description": "Retatrutide (also coded LY3437943) is an investigational once-weekly triple-agonist at the GLP-1, GIP, and glucagon receptors — the third-generation incretin-based therapy developed by Eli Lilly. Where Semaglutide activates GLP-1 alone and Tirzepatide activates both GLP-1 and GIP, retatrutide adds…", "url": "https://www.bodyhackguide.co/compound/retatrutide", "category": "Metabolic & Weight Loss", "offers": { "@type": "AggregateOffer", "lowPrice": "79.99", "priceCurrency": "USD", "offerCount": 12 } } }, { "@type": "ListItem", "position": 2, "item": { "@type": "Product", "name": "Tirzepatide", "description": "Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid synthetic peptide based on the native GIP sequence with modifications that confer…", "url": "https://www.bodyhackguide.co/compound/tirzepatide", "category": "Metabolic & Weight Loss", "offers": { "@type": "AggregateOffer", "lowPrice": "49.00", "priceCurrency": "USD", "offerCount": 17 } } } ] } }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What's the difference between Retatrutide and Tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "Retatrutide is a metabolic & weight loss that retatrutide is a 39-amino-acid synthetic peptide with balanced agonist activity at three receptors: glp-1r, gipr, and gcgr (glucagon receptor). it is chemically modified with a c20…. Tirzepatide is a metabolic & weight loss that dual glp-1 and gip receptor agonism tirzepatide simultaneously activates two incretin receptors: the glp-1 receptor and the gip receptor. while the glp-1 receptor component…. The two differ in mechanism, half-life (~6 days (plasma, albumin-bound) vs ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification), and typical dose range." } }, { "@type": "Question", "name": "Which has the longer half-life, Retatrutide or Tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "Retatrutide has a half-life of ~6 days (plasma, albumin-bound). Tirzepatide has a half-life of ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification. Longer half-lives generally mean less frequent dosing but slower on/off kinetics." } }, { "@type": "Question", "name": "Which is cheaper, Retatrutide or Tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "Current lowest live price on BodyHackGuide: Retatrutide from $79.99, Tirzepatide from $49.00. Prices are pulled from the vendor listings tracked on BHG and change frequently — see the compare tables on each compound page for the current set of offers." } }, { "@type": "Question", "name": "Can you stack Retatrutide and Tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "Stacking depends on mechanism overlap, safety profile, and goals. Retatrutide and Tirzepatide should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds." } }, { "@type": "Question", "name": "Is retatrutide stronger than tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "At their highest published doses (retatrutide 12 mg weekly vs tirzepatide 15 mg weekly), retatrutide produced 24.2% body-weight loss at 48 weeks in Phase 2, vs tirzepatide's 22.5% at 72 weeks in SURMOUNT-1. Retatrutide's curve was still descending at trial end, so the gap likely widens with longer follow-up. The 'stronger' framing assumes you tolerate the higher dose — both require slow titration to manage GI side effects." } }, { "@type": "Question", "name": "Can you switch from tirzepatide to retatrutide?", "acceptedAnswer": { "@type": "Answer", "text": "Most users cross-titrate over 2-4 weeks: hold the last tirzepatide dose, then start retatrutide at 2-4 mg weekly and escalate from there. Direct dose-matching doesn't work cleanly because the receptor profiles differ — retatrutide's glucagon arm changes satiety + metabolic dynamics. Track resting heart rate during the switch (retatrutide can add 3-5 bpm) and watch for GI re-flare during the first 2-3 weeks at any new dose." } }, { "@type": "Question", "name": "Will retatrutide get FDA approval?", "acceptedAnswer": { "@type": "Answer", "text": "Phase 3 TRIUMPH-1 readout is expected late 2026 / early 2027. Eli Lilly has signaled retatrutide as the successor to tirzepatide in their obesity pipeline. Approval timeline assumes positive Phase 3 — likely late 2027 / 2028 for an obesity indication." } }, { "@type": "Question", "name": "Which has fewer side effects, retatrutide or tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "Front-end GI profiles are nearly identical (nausea 40-60%, vomiting 15-25%, diarrhea 15-30%). Tirzepatide has the longer post-market safety record (FDA-approved 2022). Retatrutide adds a transient resting heart-rate bump (+3-5 bpm) from its glucagon arm and a small rate of mild liver enzyme elevation in Phase 2 (<5% > 3× ULN). Both share the thyroid C-cell tumor boxed warning from the GLP-1 class." } }, { "@type": "Question", "name": "How much weight will I lose on retatrutide vs tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "Trial means: tirzepatide at 15 mg = ~22.5% body weight at 72 weeks. Retatrutide at 12 mg = ~24.2% at 48 weeks. Individual response varies widely — about 30% of trial subjects in the top-dose arms exceeded 30% weight loss. Plan for a slower titration (2.5-4 mg/month dose increases) and 12-18 months total to plateau regardless of which molecule." } }, { "@type": "Question", "name": "Can you stack retatrutide and tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "No — they hit overlapping receptors (GLP-1 + GIP) and stacking would compound side effects without proportional efficacy gain. The published research on both is monotherapy. If you want triple-agonist coverage, retatrutide alone provides it. If you want dual agonist with pharmacy access, tirzepatide alone is the answer. Pick one." } }, { "@type": "Question", "name": "How do I switch from tirzepatide to retatrutide?", "acceptedAnswer": { "@type": "Answer", "text": "The standard cross-titration is a 2-3 week hold on tirzepatide (let receptor saturation drop), then start retatrutide at 2-4 mg/wk and escalate +2 mg every 4 weeks to 8-12 mg maintenance. Expect a controlled GI re-flare during week 1-2 of retatrutide. Track CMP + resting heart rate during titration (retatrutide's glucagon arm adds +3-5 bpm + occasional mild ALT elevation). Full step-by-step protocol at /blog/tirzepatide-to-retatrutide-switch-protocol." } } ] } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompare%2Fretatrutide-vs-tirzepatide) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compare](/compare) 3. Retatrutide vs Tirzepatide # Retatrutide vs Tirzepatide Side-by-side comparison of Retatrutide and Tirzepatide: mechanism, half-life, dose range, safety profile, and live vendor pricing. Updated continuously as new research and listings land. Retatrutide from $79.99 Tirzepatide from $49.00 ## Live price snapshot ### Retatrutide Current low $199.99 as of Sep 5, 2026 7-day low $199.99 30-day low $199.99 30-day change — baseline building ### Tirzepatide Current low $69.99 as of Sep 5, 2026 7-day low $69.99 30-day low $69.99 30-day change — baseline building ## Retatrutide Featured Retatrutide (also coded LY3437943) is an investigational once-weekly triple-agonist at the GLP-1, GIP, and glucagon receptors — the third-generation incretin-based therapy developed by Eli Lilly. Where Semaglutide… **Live lowest price:** $79.99 across 12 vendors [Full Retatrutide profile](/compound/retatrutide) ## Tirzepatide Featured Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid… **Live lowest price:** $49.00 across 17 vendors [Full Tirzepatide profile](/compound/tirzepatide) ## Side-by-side comparison Attribute Retatrutide Tirzepatide Category Metabolic & Weight Loss Metabolic & Weight Loss Research Stage Phase III FDA Approved Mechanism of Action Retatrutide is a 39-amino-acid synthetic peptide with balanced agonist activity at three receptors: GLP-1R, GIPR, and GCGR (glucagon receptor). It is chemically modified with a C20 fatty diacid side chain (similar to semaglutide) to bind albumin and extend its… Dual GLP-1 and GIP Receptor Agonism Tirzepatide simultaneously activates two incretin receptors: the GLP-1 receptor and the GIP receptor. While the GLP-1 receptor component provides the well-established effects of GLP-1 agonism (glucose-dependent insulin… Half-Life ~6 days (plasma, albumin-bound) ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification Typical Dose Range 1,000–12,000 mcg (1–12 mg) per week 2500 mcg (2.5 mg) starting dose, titrated every 4 weeks through 5000, 7500, 10000, 12500, to 15000 mcg (15 mg) maximum weekly dose Dosing Frequency Once weekly subcutaneous injection Once weekly subcutaneous injection Administration subcutaneous Subcutaneous (weekly) Side Effects Retatrutide has a GLP-1-class side-effect profile with additional considerations from its GIP and glucagon receptor components. Common (10% of Phase 2 participants) - Nausea — most frequent adverse event; dose-related; typically worst in first 2-4 weeks of… Mild to moderate nausea (especially at initiation), headache, fatigue, constipation or diarrhea, abdominal distension. Injection site reactions. Rare: hypoglycemia, increased heart rate, pancreatitis. Molecular Weight 4731 g/mol 4813.5 Da Common Vial Sizes 5mg, 10mg 5mg, 10mg, 15mg ## Price History 7 data points - OF - BM - Unknown - VANDL Labs - Unknown - Ion Peptide - BHG Labs - Disguised Alpha ## Price History 5 data points - OF - BM - Unknown - VANDL Labs - Ion Peptide - Disguised Alpha ### Retatrutide — potential benefits - Body weight reduction up to 24% at 48 weeks (Phase 2 data) - Glycemic control in T2DM — HbA1c reduction similar to tirzepatide - Hepatic fat reduction — potential MASH/NAFLD therapeutic effect - Modest increase in resting energy expenditure (3-5%) - Preferential visceral fat reduction - Blood pressure and lipid profile improvement (secondary to weight loss) - Once-weekly dosing convenience - Strongest non-surgical weight loss demonstrated in clinical trials to date ### Tirzepatide — potential benefits - Mean body weight reduction of 22.5% at 72 weeks - highest of any anti-obesity medication (PMID: 35658024) - 36.2% of participants achieved greater than or equal to 25% body weight loss (PMID: 35658024) - Significant HbA1c reduction in type 2 diabetes (up to 2.4% at 40 weeks in the SURPASS-5 add-on-to-insulin trial) (PMID: 35133415) - Potentially superior lean mass preservation versus GLP-1-only agents due to GIP component - Dual incretin mechanism providing complementary metabolic benefits - Improved lipid profiles including triglycerides, LDL cholesterol, and HDL cholesterol - Reduction in waist circumference and markers of visceral adiposity (PMID: 37840095) In-depth comparison ## Retatrutide vs Tirzepatide: the long answer Retatrutide is a triple agonist (GIP + GLP-1 + glucagon) currently in Phase 3; phase-2 readouts showed ~24% body-weight loss at 48 weeks at the 12 mg dose. Tirzepatide is the FDA-approved dual agonist (GIP + GLP-1) marketed as Mounjaro/Zepbound; SURMOUNT-1 hit 22.5% at 72 weeks at the 15 mg dose. Retatrutide loses more weight faster on paper but isn't FDA-approved yet, so cost and access dominate the practical decision today. Last reviewed: May 17, 2026 ### Mechanism — why the third receptor changes the math Both drugs are incretin mimetics, meaning they amplify the same satiety + insulin-secretion pathways your gut hormones already use after a meal. Tirzepatide hits two receptors: GLP-1 (slows gastric emptying, lowers appetite, improves insulin sensitivity) and GIP (potentiates GLP-1 action and may have direct adipose effects). Retatrutide adds a third leg: glucagon receptor agonism, which increases resting energy expenditure and stimulates hepatic lipolysis. In practice that means retatrutide users tend to report higher daily calorie burn at the same intake — the trial data backs this up with steeper weight-loss curves through 48 weeks with no apparent plateau. - **Tirzepatide receptors:** GLP-1 + GIP (dual agonist) - **Retatrutide receptors:** GLP-1 + GIP + glucagon (triple agonist) - **Why the third matters:** Glucagon agonism raises resting metabolic rate ~5-10% and drives hepatic fat clearance — neither dual agonist has this lever. ### Efficacy — head-to-head trial readouts Tirzepatide's SURMOUNT-1 trial (NEJM 2022, 2,539 adults) showed mean weight loss of 15.0%, 19.5%, and 22.5% at 5 mg, 10 mg, and 15 mg weekly doses through 72 weeks. Retatrutide's Phase 2 trial (NEJM 2023, 338 adults) showed 12.7%, 17.5%, 22.8%, and 24.2% at 1, 4, 8, and 12 mg weekly through just 48 weeks — meaningful because the curve was still descending at trial end. Apples-to-apples is hard because trial durations differ, but the slope through the first 48 weeks favors retatrutide. The Phase 3 TRIUMPH-1 readout is expected in late 2026. - **Tirzepatide @ 15 mg (72 wk):** 22.5% mean body-weight loss (SURMOUNT-1) - **Retatrutide @ 12 mg (48 wk):** 24.2% mean body-weight loss (Phase 2) - **Retatrutide @ 12 mg (24 wk):** 17.5% mean — fastest descent in the class to date ### Dosing — escalation protocols Both drugs require slow titration to manage GI side effects. Tirzepatide's label protocol starts at 2.5 mg weekly and escalates by 2.5 mg every 4 weeks to a maintenance dose between 5-15 mg. Retatrutide's Phase 2 protocol started at 2 mg and escalated to 4, 8, or 12 mg every 4 weeks. Research-use retatrutide users on r/Retatrutide commonly mirror this — starting at 1-2 mg, holding 2 weeks, escalating by 2 mg per step until satiety + side effects stabilize. Both injections are once weekly subcutaneous (abdomen, thigh, or upper arm). Reconstitute, store refrigerated 4-30 days depending on bacteriostatic water. - **Tirzepatide titration:** 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, +1 step every 4 weeks - **Retatrutide titration:** 2 → 4 → 8 → 12 mg, +1 step every 4 weeks (Phase 2 protocol) - **Reconstitution:** Both: subQ once weekly, BAC water, swirl don't shake — use the BHG reconstitution calc for exact dose math. ### Safety — GI dominates, hepatic is the tail risk Both drugs share a near-identical front-end side-effect profile: nausea (40-60% of users), vomiting (15-25%), diarrhea/constipation (15-30%), and decreased appetite (the goal, but uncomfortable in week 1-2 of each new dose). What differs at the tail: retatrutide's glucagon agonism produces small transient elevations in heart rate (+3-5 bpm) and very rare cases of mild hepatic enzyme elevation. Tirzepatide has a longer post-market safety record (FDA-approved May 2022) with no novel signals beyond the GLP-1 class. Both carry the boxed warning for thyroid C-cell tumor risk (rodent finding, no confirmed human signal). - **Shared GI side effects:** Nausea ~50%, vomiting ~20%, diarrhea or constipation ~25% — peaks during titration, fades by week 4 of each dose - **Retatrutide-specific:** Transient HR +3-5 bpm, rare mild ALT/AST elevation (Phase 2: <5% > 3× ULN) - **Tirzepatide-specific:** No novel signals vs class. Strong post-market data since 2022. - **Shared boxed warning:** Thyroid C-cell tumor risk — rodent finding, contraindicated in MEN-2 or personal/family history of medullary thyroid carcinoma ### Cost — what you actually pay per kg lost Tirzepatide (Mounjaro/Zepbound) retails ~$1,000-1,200/month through US pharmacies; compounded versions ran $250-500/month before FDA enforcement in late 2024 mostly shut that channel down. Insurance coverage is mixed — diabetes indication is broadly covered, obesity less so. Retatrutide is not FDA-approved, so there is no pharmacy channel. Research-use retatrutide tracked on BHG runs roughly $0.16-0.42/mg depending on vendor, putting a 12 mg/wk protocol at ~$8-20/week in raw molecule cost. Total cost per kg lost over a 48-week protocol comes out heavily in retatrutide's favor today, but that gap closes once retatrutide hits pharmacy channels in 2027+. - **Tirzepatide retail:** $1,000-1,200/month US pharmacy; insurance varies by indication - **Retatrutide research-use:** $0.16-0.42/mg → ~$8-20/week at 12 mg dose - **Live prices:** Both compounds track live on BHG via /compound/retatrutide and /compound/tirzepatide ### Who chooses which If you want an FDA-approved, prescribed, pharmacy-dispensed product with insurance leverage and the longest safety record: tirzepatide. If you want the steepest weight-loss curve published to date and you understand the research-use pathway (no prescription, vendor due diligence on you, COA verification required): retatrutide. Both are once-weekly subQ. Both require titration. Both will plateau eventually — for most users that's around month 12-18 regardless of which molecule. - **Choose tirzepatide if:** You want pharmacy + prescription, insurance coverage, fastest path to legal supply - **Choose retatrutide if:** You prioritize maximum weight loss, lowest per-mg cost, and you've verified your vendor's COA + are tracking your own labs ## Frequently asked ### What's the difference between Retatrutide and Tirzepatide? Retatrutide is a metabolic & weight loss that retatrutide is a 39-amino-acid synthetic peptide with balanced agonist activity at three receptors: glp-1r, gipr, and gcgr (glucagon receptor). it is chemically modified with a c20…. Tirzepatide is a metabolic & weight loss that dual glp-1 and gip receptor agonism tirzepatide simultaneously activates two incretin receptors: the glp-1 receptor and the gip receptor. while the glp-1 receptor component…. The two differ in mechanism, half-life (~6 days (plasma, albumin-bound) vs ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification), and typical dose range. ### Which has the longer half-life, Retatrutide or Tirzepatide? Retatrutide has a half-life of ~6 days (plasma, albumin-bound). Tirzepatide has a half-life of ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification. Longer half-lives generally mean less frequent dosing but slower on/off kinetics. ### Which is cheaper, Retatrutide or Tirzepatide? Current lowest live price on BodyHackGuide: Retatrutide from $79.99, Tirzepatide from $49.00. Prices are pulled from the vendor listings tracked on BHG and change frequently — see the compare tables on each compound page for the current set of offers. ### Can you stack Retatrutide and Tirzepatide? Stacking depends on mechanism overlap, safety profile, and goals. Retatrutide and Tirzepatide should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds. ### Is retatrutide stronger than tirzepatide? At their highest published doses (retatrutide 12 mg weekly vs tirzepatide 15 mg weekly), retatrutide produced 24.2% body-weight loss at 48 weeks in Phase 2, vs tirzepatide's 22.5% at 72 weeks in SURMOUNT-1. Retatrutide's curve was still descending at trial end, so the gap likely widens with longer follow-up. The 'stronger' framing assumes you tolerate the higher dose — both require slow titration to manage GI side effects. ### Can you switch from tirzepatide to retatrutide? Most users cross-titrate over 2-4 weeks: hold the last tirzepatide dose, then start retatrutide at 2-4 mg weekly and escalate from there. Direct dose-matching doesn't work cleanly because the receptor profiles differ — retatrutide's glucagon arm changes satiety + metabolic dynamics. Track resting heart rate during the switch (retatrutide can add 3-5 bpm) and watch for GI re-flare during the first 2-3 weeks at any new dose. ### Will retatrutide get FDA approval? Phase 3 TRIUMPH-1 readout is expected late 2026 / early 2027. Eli Lilly has signaled retatrutide as the successor to tirzepatide in their obesity pipeline. Approval timeline assumes positive Phase 3 — likely late 2027 / 2028 for an obesity indication. ### Which has fewer side effects, retatrutide or tirzepatide? Front-end GI profiles are nearly identical (nausea 40-60%, vomiting 15-25%, diarrhea 15-30%). Tirzepatide has the longer post-market safety record (FDA-approved 2022). Retatrutide adds a transient resting heart-rate bump (+3-5 bpm) from its glucagon arm and a small rate of mild liver enzyme elevation in Phase 2 (<5% > 3× ULN). Both share the thyroid C-cell tumor boxed warning from the GLP-1 class. ### How much weight will I lose on retatrutide vs tirzepatide? Trial means: tirzepatide at 15 mg = ~22.5% body weight at 72 weeks. Retatrutide at 12 mg = ~24.2% at 48 weeks. Individual response varies widely — about 30% of trial subjects in the top-dose arms exceeded 30% weight loss. Plan for a slower titration (2.5-4 mg/month dose increases) and 12-18 months total to plateau regardless of which molecule. ### Can you stack retatrutide and tirzepatide? No — they hit overlapping receptors (GLP-1 + GIP) and stacking would compound side effects without proportional efficacy gain. The published research on both is monotherapy. If you want triple-agonist coverage, retatrutide alone provides it. If you want dual agonist with pharmacy access, tirzepatide alone is the answer. Pick one. ### How do I switch from tirzepatide to retatrutide? The standard cross-titration is a 2-3 week hold on tirzepatide (let receptor saturation drop), then start retatrutide at 2-4 mg/wk and escalate +2 mg every 4 weeks to 8-12 mg maintenance. Expect a controlled GI re-flare during week 1-2 of retatrutide. Track CMP + resting heart rate during titration (retatrutide's glucagon arm adds +3-5 bpm + occasional mild ALT elevation). Full step-by-step protocol at /blog/tirzepatide-to-retatrutide-switch-protocol. ## See current vendor prices Live listings from the vendors we track, refreshed continuously. [Retatrutide prices](/compound/retatrutide?tab=prices) [Tirzepatide prices](/compound/tirzepatide?tab=prices) [Compare all compounds](/compare) ### Before you buy Retatrutide or Tirzepatide Check the vendor trust score. Every supplier we track is rated 0–100 on COA verification, payment transparency, shipping, reviews, and listings — one published, reproducible methodology, applied to every vendor including BHG Labs, which shares our ownership. [View Vendor Scorecard](/vendors/scorecard) ## Related comparisons [Tirzepatide vs Semaglutide](/compare/tirzepatide-vs-semaglutide)[Retatrutide vs Semaglutide](/compare/retatrutide-vs-semaglutide)[Mazdutide vs Tirzepatide](/compare/mazdutide-vs-tirzepatide)[AOD-9604 vs Tirzepatide](/compare/aod-9604-vs-tirzepatide)[5-Amino-1MQ vs Tirzepatide](/compare/5-amino-1mq-vs-tirzepatide)[Orforglipron vs Semaglutide](/compare/orforglipron-vs-semaglutide)[AOD-9604 vs Semaglutide](/compare/aod-9604-vs-semaglutide) **Research use only.** BodyHackGuide is a research and price-comparison reference. BodyHackGuide and BHG Labs share common ownership. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks, and every vendor is ranked on the same public, reproducible methodology. See [editorial standards](/editorial-standards) and [affiliate disclosure](/affiliate-disclosure). ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) [Shop BHG Labs · 20% off with BHG20](https://bhglabs.co/shop/?utm_source=reddit&utm_medium=paid&utm_campaign=bhg20_bridge&utm_content=sticky_mobile_bar&ref=zmgqyxku&coupon=BHG20) hi 👋